Laikai Pharmaceutical-B (02105) has completed the treatment of the low dose group of LAE102 in the 24-week monotherapy study

Zhitong Finance App News, Laikai Pharmaceutical-B (02105) announced that the Group has completed the LAE102 24-week single-drug treatment study for the low dose group treatment. This data is consistent with LAE102's previous single dose escalation (SAD) and multiple dose escalation (MAD) studies, showing positive changes in body composition. Of particular note, the completed low dose group showed encouraging weight loss results, with muscle gain and fat loss observed. The 24-week treatment was well tolerated. No serious adverse events were reported, and no reports of diarrhea, muscle cramps, or acne were reported, which is consistent with the SAD and MAD findings previously disclosed.

A high-concentration LAE102 formulation has recently been prepared, and the Group has completed the enrollment of subjects in the high-dose group to further evaluate the efficacy and safety of LAE102 at high dosage levels during the 24-week treatment period.

Currently, the Group is actively seeking partners with global capabilities to accelerate the global development and commercialization process of LAE102. The Group is committed to providing this precise treatment for patients with obesity or metabolic diseases who require novel treatment options to achieve high-quality weight management.